NCT04807127 is a clinical trial of Immune checkpoint blockade in Pneumonitis, Interstitial, sponsored by Universitaire Ziekenhuizen KU Leuven.

Who is sponsoring NCT04807127?

NCT04807127 is sponsored by Universitaire Ziekenhuizen KU Leuven.

What drugs are being tested in NCT04807127?

Interventions in NCT04807127: Immune checkpoint blockade, Targeted therapy, Radiotherapy.

What condition does NCT04807127 study?

NCT04807127 studies Pneumonitis, Interstitial, Immunotherapy, Immune-related Adverse Events.

Is NCT04807127 still recruiting?

NCT04807127 is currently recruiting now. Last updated 1 July 2024.

Last reviewed 2024-07-01 · How we verify

NCT04807127

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade

Recruiting now Last updated 1 July 2024

What this trial tests

trial testing Immune checkpoint blockade in Pneumonitis, Interstitial in 60 participants. Currently enrolling.

Timeline

1 February 2020

Primary endpoint
31 January 2025

31 January 2025

Quick facts

Lead sponsor	Universitaire Ziekenhuizen KU Leuven
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	60
Start date	1 February 2020
Primary completion	31 January 2025
Estimated completion	31 January 2025
Sites	1 location across Belgium

Drugs / interventions tested

Immune checkpoint blockade — full drug profile →
Targeted therapy — full drug profile →
Radiotherapy — full drug profile →

Conditions studied

Pneumonitis, Interstitial — all drugs for Pneumonitis, Interstitial →
Immunotherapy — all drugs for Immunotherapy →
Immune-related Adverse Events — all drugs for Immune-related Adverse Events →

Sponsor

Universitaire Ziekenhuizen KU Leuven — full company profile →

Who can join

Adults 18 to 120, any sex, with Pneumonitis, Interstitial or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main goal of this prospective non-interventional exploratory monocentric study is to characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from cancer patients experiencing cancer therapy-induced pneumonitis on a single-cell scale. These mechanistic insights can directly lead to putative diagnostic biomarkers and therapeutic targets. A second highly clinically relevant hypothesis is that single-cell profiling of blood samples will reveal circulating biomarkers of ICB toxicity, making non-invasive diagnosis feasible.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events.
Smithy JW, Faleck DM, Postow MA. · · 2022 · cited 25× · PMID 34921018 · DOI 10.1158/1078-0432.ccr-21-1240
Single-Cell Sequencing: Current Applications in Precision Onco-Genomics and Cancer Therapeutics.
Mustachio LM, Roszik J. · · 2022 · cited 18× · PMID 35158925 · DOI 10.3390/cancers14030657

Verify or expand the search:

Other Universitaire Ziekenhuizen KU Leuven trials

Trials by the same sponsor.

NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04807127 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
Last refreshed: 1 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04807127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing